Virtual Library
Start Your Search
P. Liv
Author of
-
+
P1.14 - Radiotherapy (ID 700)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Radiotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.14-008 - Elevated Platelet Levels Affect Prognosis in Patients with NSCLC Treated with Curatively Intended Chemoradiotherapy (ID 7528)
09:30 - 09:30 | Author(s): P. Liv
- Abstract
Background:
For inoperable stage III NSCLC, chemoradiotherapy is the standard of care. However, this treatment is associated with significant side effects and only offers a small chance of cure. Having adequate prognostic information at the start of treatment is essential in order to select the most appropriate treatment strategy for each individual patient. This study investigates the prognostic value of pre-treatment platelet (Plt) levels in this treatment setting.
Method:
Data were collected retrospectively from two phase II trials conducted from 2002 to 2007 in Sweden with patients treated with chemoradiotherapy for stage IIIA-IIIB NSCLC. Clinical and laboratory data at enrollment were collected for all patients and studied in relation to overall survival using Kaplan-Meier product-limit estimates and a multivariate Cox regression model. An optimal prognostic cut-off point for Plt was estimated by using a stepwise log-rank testing of survival comparing patients with a Plt count below and above every Plt count in the dataset. The cut-off point was defined as the Plt count that gave the lowest p-value using the log-rank test.
Result:
Patients with thrombocytosis (defined as Plt > 350 x 10[9]/L) had a shorter median overall survival than patients with normal Plt (≤ 350 x 10[9]/L) at baseline (14.5 and 23.7 months, respectively), which was statistically significant (p=0.0025). This significant association was retained in a multivariate model where other laboratory and clinical factors, such as performance status, were included. The optimal prognostic cut-off point for platelet levels in this patient material was estimated at Plt = 610. Figure 1
Conclusion:
In stage III NSCLC treated with curatively intended chemoradiotherapy, elevated platelet levels showed to be an independent prognostic marker for shorter overall survival. Further research is needed to establish the role of platelet levels and appropriate cut-off limits when making treatment decisions in this clinical setting.
